| Full text | |
| Author(s): |
Renata Portella Nunes
;
Flávio Eduardo Hirai
[2]
;
Eduardo Buchelle Rodrigues
[3]
;
Michel Eid Farah
[4]
Total Authors: 4
|
| Document type: | Journal article |
| Source: | Arquivos Brasileiros de Oftalmologia; v. 83, n. 1, p. 48-54, 2020-02-27. |
| Abstract | |
ABSTRACT Purpose: To study the cost-effectiveness of ranibizumab and bevacizumab for the treatment of age-related macular degeneration. Methods: We used a decision tree model to analyze the cost-effectiveness of ranibizumab and bevacizumab for the treatment of age-related macular degeneration, from the Brazilian Public Health System (SUS) perspective. Ranibizumab and bevacizumab were administered to patients with the same treatment procedure, and the difference in treatment costs was calculated based on the cost of the drugs. Direct costs were estimated using the information provided by the Brazilian SUS. Effectiveness in terms of quality-adjusted life years (QALYs) was calculated based on the utility values for visual impairment. Incremental cost-effectiveness ratio was calculated by comparing both treatments. The analytical horizon was one year. Results: The decision tree analysis showed that the difference in treatment effectiveness was 0.01 QALY. Incremental cost-effectiveness ratio showed that ranibizumab treatment required an incremental annual cost of more than R$ 2 million to generate 1 additional QALY, as compared to bevacizumab. Conclusions: From the Brazilian SUS perspective, bevacizumab is more cost-effective than ranibizumab for the treatment of neovascular age-related macular degeneration. Its use could allow potential annual savings in health budget. (AU) | |
| FAPESP's process: | 10/15451-0 - A study on the cost-effectiveness on the pharmacologic treatments for age-related macular degeneration |
| Grantee: | Michel Eid Farah |
| Support Opportunities: | Regular Research Grants |